CTIC Volume Alert - CTIC 2.13 Cell Therapeutics $CTIC Hit a high of 2.15 Currently 11/07/14 Last price 2.13 -0.23 -9.75% With a day low of 2.00 and a current volume of 15,369,700.
CTIC Cell Therapeutics Recent Headline News
Cell Therapeutics Down 13.8%, Shares Slide into the Red (CTIC)
Comtex SmarTrend(R) - Fri Nov 07, 10:08AM CST
Cell Therapeutics (NASDAQ:CTIC) is one of today's worst performing low-priced stocks, down 13.8% to $2.04 on 8.4x average daily volume. Cell Therapeutics has traded 8.1 million shares thus far today, vs. average volume of 972,000 shares per day. The stock has underperformed the Dow (-13.8% to the Dow's -0.0%) and underperformed the S&P 500 (-13.8% to the S&P's 0.1%) during today's trading.
CTIC: 2.13 (-0.23)
Insider Trading Alert - CTIC, SAM And DGI Traded By Insiders
at The Street - Fri Nov 07, 10:00AM CST
Stocks with insider trader activity include CTIC, SAM and DGI
DGI: 28.95 (+0.21), SAM: 258.90 (+0.46), CTIC: 2.13 (-0.23)
CTI BioPharma Prices Underwritten Public Offering of $35 Million of Convertible Preferred Stock
PR Newswire - Fri Nov 07, 8:15AM CST
CTI BioPharma Corp. ("CTI"
(NASDAQ and MTA: CTIC) today announced the pricing of an underwritten public offering of 35,000 shares of its Series 21 Preferred Stock, offered at a price to the public of $1,000 per share of Series 21 Preferred Stock (the "Offering" . Each share of Series 21 Preferred Stock is convertible at the option of the holder, at any time, into 500 shares of common stock at a conversion price of $2.00 per share of common stock, for a total of 17.5 million shares of common stock. The shares of Series 21 Preferred Stock will automatically convert into shares of common stock in certain circumstances. Shares of the Series 21 Preferred Stock will receive dividends in the same amount as any dividends declared and paid on shares of common stock, but would be entitled to a liquidation preference over the common stock in certain liquidation events. The Series 21 Preferred Stock will have no voting rights on general corporate matters.
CTIC: 2.13 (-0.23)
CTI BioPharma Announces Proposed Public Offering of Convertible Preferred Stock
PR Newswire - Thu Nov 06, 3:15PM CST
CTI BioPharma Corp. ("CTI" (NASDAQ and MTA: CTIC) today announced that it intends to offer and sell, subject to market and other conditions, shares of its Series 21 Preferred Stock in an underwritten public offering(the "Offering" . Each share of Series 21 Preferred Stock will have a stated value of $1,000 per share and will be convertible at the option of the holder, at any time after issuance, into shares of common stock prior to the automatic conversion of such shares in certain circumstances. Shares of the Series 21 Preferred Stock will receive dividends in the same amount as any dividends declared and paid on shares of common stock, but would be entitled to a liquidation preference over the common stock in certain liquidation events. The Series 21 Preferred Stock will have no voting rights on general corporate matters.
CTIC: 2.13 (-0.23)
CTI BioPharma Reports Third Quarter 2014 Financial Results
PR Newswire - Wed Oct 29, 3:01PM CDT
CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) today reported financial results for the three months ended September 30, 2014.
CTIC: 2.13 (-0.23)
CTI Acquires Exclusive Worldwide License to Tosedostat, a Selective Oral Anti-Cancer Therapy
PR Newswire - Mon Oct 27, 1:30AM CDT
CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) today announced that it has acquired worldwide rights to tosedostat through concurrent transactions with Vernalis R&D Limited (Vernalis), the originator of tosedostat, and Chroma Therapeutics Ltd. (Chroma), through which CTI previously held a sublicense with respect to tosedostat in North, Central and South America. Tosedostat is a first-in-class selective inhibitor of aminopeptidases, which are required by tumor cells to provide amino acids necessary for growth and tumor cell survival. Tosedostat is currently being evaluated in multiple Phase 2 clinical trials for the treatment of patients with Acute Myeloid Leukemia (AML) or high-risk Myelodysplastic Syndrome (MDS), which are intended to inform the design for a Phase 3 registration study to support potential regulatory approval.
CTIC: 2.13 (-0.23)
CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014
PR Newswire - Mon Oct 20, 12:30AM CDT
CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) announced today that it will report its third quarter 2014 financial results on Wednesday, October 29, 2014, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a webcast conference call to discuss the results and provide a general corporate update at 4:30 p.m. EDT (1:30 p.m. PDT). Access to the event can be obtained as follows:
CTIC: 2.13 (-0.23)
Fallopian Tube Cancer - Pipeline Review, H2 2014
M2 - Wed Oct 08, 4:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/b25z3h/fallopian_tube) has announced the addition of the "Fallopian Tube Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Fallopian Tube Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fallopian Tube Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - Johnson & Johnson - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Amgen Inc. - Eli Lilly and Company - GlaxoSmithKline plc - MedImmune, LLC - Daiichi Sankyo Company, Limited - Oxford BioMedica plc - Millennium Pharmaceuticals, Inc. - Novartis AG - Astellas Pharma Inc. - ImmunoGen, Inc. - Astex Pharmaceuticals, Inc. - CTI BioPharma Corp. - Bayer AG - Incyte Corporation - Active Biotech AB - Oncolytics Biotech Inc. - OXiGENE, Inc. - Curis - Topotarget - NeoStem - Pharmacyclics - Synta - Oasmia - MabVax - Acceleron - Cerulean - OncoMed - TetraLogic Pharmaceuticals - Merrimack Pharmaceuticals, Inc. - Immunovaccine, Inc. - Pharma Mar, S.A. - VentiRx Pharmaceuticals, Inc. - TRACON Pharmaceuticals, Inc. - Lee's Pharmaceutical Holdings Limited - Clovis Oncology, Inc. - Recepta Biopharma S.A. - EGEN, Inc. - Sanofi Pasteur SA - AbbVie Inc. For more information visit http://www.researchandmarkets.com/research/b2...opian_tube
ONCY: 0.70 (+0.08), INCY: 69.32 (+0.92), IMGN: 9.77 (+0.11), AMGN: 160.25 (-0.10), LLY: 66.60 (-0.36), CTIC: 2.13 (-0.23), GSK: 44.91 (+0.16), OXGN: 2.16 (-0.02), MACK: 8.70 (-0.07), JNJ: 108.20 (-0.81), CLVS: 58.31 (-0.26), ABBV: 61.50 (-1.21), NVS: 91.76 (-0.27)
Technical Updates on Health Care Sector Stocks - AstraZeneca, Novartis, Salix Pharma, Inovio Pharma, and CTI BioPharma
PR Newswire - Mon Oct 06, 8:15AM CDT
Investor-Edge has initiated coverage on the following equities: AstraZeneca PLC (NYSE: AZN), Novartis AG (NYSE: NVS), Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), Inovio Pharmaceuticals Inc. (NASDAQ: INO), and CTI BioPharma Corporation (NASDAQ: CTIC). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Friday, October 03, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,009.69, up 1.24% and the NASDAQ Composite closed at 4,475.62, up 1.03%. The S&P 500 finished the session 1.12% higher at 1,967.90. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 745.09, up 1.97%, with the index advancing 3.29% in the previous three months. Register for your complimentary reports on these five stocks at:
INO: 11.23 (+0.16), AZN: 72.88 (+0.03), SLXP: 91.47 (-47.08), CTIC: 2.13 (-0.23), NVS: 91.76 (-0.27)
Micro-Cap Biotechs: The Next Billion Dollar Drug Is Coming From...?
OptionVol - Thu Oct 02, 5:33PM CDT
This visualization is provided by: Capital Market Laboratories (join the queue: free trial) Micro Cap Bio-techs: Who's Investing in R&D? Note that the firms above the blue line I've drawn in are pouring in at least $0.60 into researc...
LOXO: 12.00 (+0.01), DNDN: 0.94 (+0.11), VNDA: 11.79 (-0.67), OSIR: 13.50 (-0.34), CLDN: 11.50 (-0.10), GALE: 1.95 (-0.09), CTIC: 2.13 (-0.23), OTIC: 24.09 (-0.06)
Merrimack Does Well to License Marginal Cancer Drug to Baxter
at The Street - Wed Sep 24, 7:14AM CDT
Baxter has a hunger for cancer drugs with hair.
MACK: 8.70 (-0.07), BAX: 70.61 (-0.99), ONTX: 4.78 (unch), CTIC: 2.13 (-0.23)
Hot Stock: Cell Therapeutics, Shares Drop 6.0% (CTIC)
Comtex SmarTrend(R) - Mon Sep 22, 11:40AM CDT
Cell Therapeutics (NASDAQ:CTIC) is one of today's worst performing low-priced stocks, down 6.0% to $2.52 on 1.0x average daily volume. Cell Therapeutics has traded 1.0 million shares thus far today, vs. average volume of 1.0 million shares per day. The stock has underperformed the Dow (-6.0% to the Dow's -0.5%) and underperformed the S&P 500 (-6.0% to the S&P's -0.8%) during today's trading.
CTIC: 2.13 (-0.23)
Traders Get Bullish on Shares of Cell Therapeutics, Shares Up 16.7% (CTIC)
Comtex SmarTrend(R) - Wed Sep 17, 10:07AM CDT
Cell Therapeutics (NASDAQ:CTIC) is one of today's best performing low-priced stocks, up 16.7% to $2.93 on 6.0x average daily volume. Thus far today, Cell Therapeutics has traded 5.2 million shares, vs. average volume of 852,000 shares per day. The stock has outperformed the Dow (16.7% to the Dow's 0.1%) and outperformed the S&P 500 (16.7% to the S&P's 0.1%) during today's trading.
CTIC: 2.13 (-0.23)
CTI BioPharma And Servier Announce Exclusive License And Collaboration Agreement To Develop And Commercialize PIXUVRI®
PR Newswire - Wed Sep 17, 12:30AM CDT
CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) and Servier today jointly announced that they have entered into an exclusive license and collaboration agreement to develop and commercialize PIXUVRI® (pixantrone) in a transaction valued at up to EUR 103.0 million (approximately $133.5 million) if all milestones are achieved. Under the agreement, CTI retains full commercialization rights for PIXUVRI in Austria, Denmark, Finland, Germany, Israel, Norway, Sweden, Turkey, the United Kingdom and the U.S., with Servier having exclusive rights to commercialize PIXUVRI in all other countries.
CTIC: 2.13 (-0.23)
SEC Slaps Biotech Hedge Fund for Short-Selling Violations
at The Street - Tue Sep 16, 12:04PM CDT
On 17 occasions, RA Capital bought shares in biotech company financings after having sold short shares of the same company when it was supposed to be restricted from doing so.
SGMO: 11.32 (-0.32), IMGN: 9.77 (+0.11), EXAS: 22.82 (-0.52), CTIC: 2.13 (-0.23), KERX: 16.73 (-0.47)
Momentum Indicators for Biotech Stocks -- Exact Sciences, BioCryst Pharma, Spectrum Pharma, Aeterna Zentaris, and CTI BioPharma
PR Newswire - Mon Aug 25, 7:50AM CDT
On Friday, August 22, 2014, the NASDAQ Composite ended at 4,538.55, up 0.14%, the Dow Jones Industrial Average declined 0.22%, to finish the day at 17,001.22, and the S&P 500 closed at 1,988.40, down 0.20%. The losses were broad based as seven out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day flat at 727.35, and the index has advanced 6.75% in the previous three months. Investor-Edge has initiated coverage on the following equities: Exact Sciences Corporation (NASDAQ: EXAS), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI), Aeterna Zentaris Inc. (NASDAQ: AEZS), and CTI BioPharma Corporation (NASDAQ: CTIC). Free research on these five companies can be accessed at:
BCRX: 10.46 (+0.14), AEZS: 0.57 (-0.08), SPPI: 7.33 (-0.15), EXAS: 22.82 (-0.52), CTIC: 2.13 (-0.23)
Insider Trading Alert - MTDR, ABCO And CTIC Traded By Insiders
at The Street - Mon Aug 18, 9:15AM CDT
Stocks with insider trader activity include MTDR, ABCO and CTIC
ABCO: 48.47 (-5.78), CTIC: 2.13 (-0.23), MTDR: 24.03 (+1.54)
Insider Trading Alert - CMS, CTIC And WFT Traded By Insiders
at The Street - Thu Aug 07, 9:15AM CDT
Stocks with insider trader activity include CMS, CTIC and WFT
CMS: 32.91 (+0.54), WFT: 15.67 (+0.29), CTIC: 2.13 (-0.23)
FDA Grants Fast Track Designation to CTI BioPharma's Pacritinib, a Novel JAK2 Inhibitor for the Treatment of Myelofibrosis
PR Newswire - Thu Aug 07, 12:30AM CDT
CTI BioPharma Corp. (CTI or the Company) (NASDAQ and MTA: CTIC) announced today that pacritinib has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of intermediate and high risk myelofibrosis, including but not limited to patients with disease related thrombocytopenia, patients experiencing treatment emergent thrombocytopenia on other JAK2 therapy or patients who are intolerant to or whose symptoms are sub-optimally managed on other JAK2 therapy. Pacritinib is an oral tyrosine kinase inhibitor with dual activity against JAK2 and FLT3. The drug candidate is currently being evaluated in two Phase 3 clinical trials, known as the PERSIST program, for patients with myelofibrosis.
CTIC: 2.13 (-0.23)
CTIC Cell Therapeutics Recent Headline News
Cell Therapeutics Down 13.8%, Shares Slide into the Red (CTIC)
Comtex SmarTrend(R) - Fri Nov 07, 10:08AM CST
Cell Therapeutics (NASDAQ:CTIC) is one of today's worst performing low-priced stocks, down 13.8% to $2.04 on 8.4x average daily volume. Cell Therapeutics has traded 8.1 million shares thus far today, vs. average volume of 972,000 shares per day. The stock has underperformed the Dow (-13.8% to the Dow's -0.0%) and underperformed the S&P 500 (-13.8% to the S&P's 0.1%) during today's trading.
CTIC: 2.13 (-0.23)
Insider Trading Alert - CTIC, SAM And DGI Traded By Insiders
at The Street - Fri Nov 07, 10:00AM CST
Stocks with insider trader activity include CTIC, SAM and DGI
DGI: 28.95 (+0.21), SAM: 258.90 (+0.46), CTIC: 2.13 (-0.23)
CTI BioPharma Prices Underwritten Public Offering of $35 Million of Convertible Preferred Stock
PR Newswire - Fri Nov 07, 8:15AM CST
CTI BioPharma Corp. ("CTI"
(NASDAQ and MTA: CTIC) today announced the pricing of an underwritten public offering of 35,000 shares of its Series 21 Preferred Stock, offered at a price to the public of $1,000 per share of Series 21 Preferred Stock (the "Offering" . Each share of Series 21 Preferred Stock is convertible at the option of the holder, at any time, into 500 shares of common stock at a conversion price of $2.00 per share of common stock, for a total of 17.5 million shares of common stock. The shares of Series 21 Preferred Stock will automatically convert into shares of common stock in certain circumstances. Shares of the Series 21 Preferred Stock will receive dividends in the same amount as any dividends declared and paid on shares of common stock, but would be entitled to a liquidation preference over the common stock in certain liquidation events. The Series 21 Preferred Stock will have no voting rights on general corporate matters. CTIC: 2.13 (-0.23)
CTI BioPharma Announces Proposed Public Offering of Convertible Preferred Stock
PR Newswire - Thu Nov 06, 3:15PM CST
CTI BioPharma Corp. ("CTI"
(NASDAQ and MTA: CTIC) today announced that it intends to offer and sell, subject to market and other conditions, shares of its Series 21 Preferred Stock in an underwritten public offering(the "Offering" . Each share of Series 21 Preferred Stock will have a stated value of $1,000 per share and will be convertible at the option of the holder, at any time after issuance, into shares of common stock prior to the automatic conversion of such shares in certain circumstances. Shares of the Series 21 Preferred Stock will receive dividends in the same amount as any dividends declared and paid on shares of common stock, but would be entitled to a liquidation preference over the common stock in certain liquidation events. The Series 21 Preferred Stock will have no voting rights on general corporate matters. CTIC: 2.13 (-0.23)
CTI BioPharma Reports Third Quarter 2014 Financial Results
PR Newswire - Wed Oct 29, 3:01PM CDT
CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) today reported financial results for the three months ended September 30, 2014.
CTIC: 2.13 (-0.23)
CTI Acquires Exclusive Worldwide License to Tosedostat, a Selective Oral Anti-Cancer Therapy
PR Newswire - Mon Oct 27, 1:30AM CDT
CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) today announced that it has acquired worldwide rights to tosedostat through concurrent transactions with Vernalis R&D Limited (Vernalis), the originator of tosedostat, and Chroma Therapeutics Ltd. (Chroma), through which CTI previously held a sublicense with respect to tosedostat in North, Central and South America. Tosedostat is a first-in-class selective inhibitor of aminopeptidases, which are required by tumor cells to provide amino acids necessary for growth and tumor cell survival. Tosedostat is currently being evaluated in multiple Phase 2 clinical trials for the treatment of patients with Acute Myeloid Leukemia (AML) or high-risk Myelodysplastic Syndrome (MDS), which are intended to inform the design for a Phase 3 registration study to support potential regulatory approval.
CTIC: 2.13 (-0.23)
CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014
PR Newswire - Mon Oct 20, 12:30AM CDT
CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) announced today that it will report its third quarter 2014 financial results on Wednesday, October 29, 2014, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a webcast conference call to discuss the results and provide a general corporate update at 4:30 p.m. EDT (1:30 p.m. PDT). Access to the event can be obtained as follows:
CTIC: 2.13 (-0.23)
Fallopian Tube Cancer - Pipeline Review, H2 2014
M2 - Wed Oct 08, 4:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/b25z3h/fallopian_tube) has announced the addition of the "Fallopian Tube Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Fallopian Tube Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fallopian Tube Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - Johnson & Johnson - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Amgen Inc. - Eli Lilly and Company - GlaxoSmithKline plc - MedImmune, LLC - Daiichi Sankyo Company, Limited - Oxford BioMedica plc - Millennium Pharmaceuticals, Inc. - Novartis AG - Astellas Pharma Inc. - ImmunoGen, Inc. - Astex Pharmaceuticals, Inc. - CTI BioPharma Corp. - Bayer AG - Incyte Corporation - Active Biotech AB - Oncolytics Biotech Inc. - OXiGENE, Inc. - Curis - Topotarget - NeoStem - Pharmacyclics - Synta - Oasmia - MabVax - Acceleron - Cerulean - OncoMed - TetraLogic Pharmaceuticals - Merrimack Pharmaceuticals, Inc. - Immunovaccine, Inc. - Pharma Mar, S.A. - VentiRx Pharmaceuticals, Inc. - TRACON Pharmaceuticals, Inc. - Lee's Pharmaceutical Holdings Limited - Clovis Oncology, Inc. - Recepta Biopharma S.A. - EGEN, Inc. - Sanofi Pasteur SA - AbbVie Inc. For more information visit http://www.researchandmarkets.com/research/b2...opian_tube
ONCY: 0.70 (+0.08), INCY: 69.32 (+0.92), IMGN: 9.77 (+0.11), AMGN: 160.25 (-0.10), LLY: 66.60 (-0.36), CTIC: 2.13 (-0.23), GSK: 44.91 (+0.16), OXGN: 2.16 (-0.02), MACK: 8.70 (-0.07), JNJ: 108.20 (-0.81), CLVS: 58.31 (-0.26), ABBV: 61.50 (-1.21), NVS: 91.76 (-0.27)
Technical Updates on Health Care Sector Stocks - AstraZeneca, Novartis, Salix Pharma, Inovio Pharma, and CTI BioPharma
PR Newswire - Mon Oct 06, 8:15AM CDT
Investor-Edge has initiated coverage on the following equities: AstraZeneca PLC (NYSE: AZN), Novartis AG (NYSE: NVS), Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), Inovio Pharmaceuticals Inc. (NASDAQ: INO), and CTI BioPharma Corporation (NASDAQ: CTIC). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Friday, October 03, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,009.69, up 1.24% and the NASDAQ Composite closed at 4,475.62, up 1.03%. The S&P 500 finished the session 1.12% higher at 1,967.90. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 745.09, up 1.97%, with the index advancing 3.29% in the previous three months. Register for your complimentary reports on these five stocks at:
INO: 11.23 (+0.16), AZN: 72.88 (+0.03), SLXP: 91.47 (-47.08), CTIC: 2.13 (-0.23), NVS: 91.76 (-0.27)
Micro-Cap Biotechs: The Next Billion Dollar Drug Is Coming From...?
OptionVol - Thu Oct 02, 5:33PM CDT
This visualization is provided by: Capital Market Laboratories (join the queue: free trial) Micro Cap Bio-techs: Who's Investing in R&D? Note that the firms above the blue line I've drawn in are pouring in at least $0.60 into researc...
LOXO: 12.00 (+0.01), DNDN: 0.94 (+0.11), VNDA: 11.79 (-0.67), OSIR: 13.50 (-0.34), CLDN: 11.50 (-0.10), GALE: 1.95 (-0.09), CTIC: 2.13 (-0.23), OTIC: 24.09 (-0.06)
Merrimack Does Well to License Marginal Cancer Drug to Baxter
at The Street - Wed Sep 24, 7:14AM CDT
Baxter has a hunger for cancer drugs with hair.
MACK: 8.70 (-0.07), BAX: 70.61 (-0.99), ONTX: 4.78 (unch), CTIC: 2.13 (-0.23)
Hot Stock: Cell Therapeutics, Shares Drop 6.0% (CTIC)
Comtex SmarTrend(R) - Mon Sep 22, 11:40AM CDT
Cell Therapeutics (NASDAQ:CTIC) is one of today's worst performing low-priced stocks, down 6.0% to $2.52 on 1.0x average daily volume. Cell Therapeutics has traded 1.0 million shares thus far today, vs. average volume of 1.0 million shares per day. The stock has underperformed the Dow (-6.0% to the Dow's -0.5%) and underperformed the S&P 500 (-6.0% to the S&P's -0.8%) during today's trading.
CTIC: 2.13 (-0.23)
Traders Get Bullish on Shares of Cell Therapeutics, Shares Up 16.7% (CTIC)
Comtex SmarTrend(R) - Wed Sep 17, 10:07AM CDT
Cell Therapeutics (NASDAQ:CTIC) is one of today's best performing low-priced stocks, up 16.7% to $2.93 on 6.0x average daily volume. Thus far today, Cell Therapeutics has traded 5.2 million shares, vs. average volume of 852,000 shares per day. The stock has outperformed the Dow (16.7% to the Dow's 0.1%) and outperformed the S&P 500 (16.7% to the S&P's 0.1%) during today's trading.
CTIC: 2.13 (-0.23)
CTI BioPharma And Servier Announce Exclusive License And Collaboration Agreement To Develop And Commercialize PIXUVRI®
PR Newswire - Wed Sep 17, 12:30AM CDT
CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) and Servier today jointly announced that they have entered into an exclusive license and collaboration agreement to develop and commercialize PIXUVRI® (pixantrone) in a transaction valued at up to EUR 103.0 million (approximately $133.5 million) if all milestones are achieved. Under the agreement, CTI retains full commercialization rights for PIXUVRI in Austria, Denmark, Finland, Germany, Israel, Norway, Sweden, Turkey, the United Kingdom and the U.S., with Servier having exclusive rights to commercialize PIXUVRI in all other countries.
CTIC: 2.13 (-0.23)
SEC Slaps Biotech Hedge Fund for Short-Selling Violations
at The Street - Tue Sep 16, 12:04PM CDT
On 17 occasions, RA Capital bought shares in biotech company financings after having sold short shares of the same company when it was supposed to be restricted from doing so.
SGMO: 11.32 (-0.32), IMGN: 9.77 (+0.11), EXAS: 22.82 (-0.52), CTIC: 2.13 (-0.23), KERX: 16.73 (-0.47)
Momentum Indicators for Biotech Stocks -- Exact Sciences, BioCryst Pharma, Spectrum Pharma, Aeterna Zentaris, and CTI BioPharma
PR Newswire - Mon Aug 25, 7:50AM CDT
On Friday, August 22, 2014, the NASDAQ Composite ended at 4,538.55, up 0.14%, the Dow Jones Industrial Average declined 0.22%, to finish the day at 17,001.22, and the S&P 500 closed at 1,988.40, down 0.20%. The losses were broad based as seven out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day flat at 727.35, and the index has advanced 6.75% in the previous three months. Investor-Edge has initiated coverage on the following equities: Exact Sciences Corporation (NASDAQ: EXAS), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI), Aeterna Zentaris Inc. (NASDAQ: AEZS), and CTI BioPharma Corporation (NASDAQ: CTIC). Free research on these five companies can be accessed at:
BCRX: 10.46 (+0.14), AEZS: 0.57 (-0.08), SPPI: 7.33 (-0.15), EXAS: 22.82 (-0.52), CTIC: 2.13 (-0.23)
Insider Trading Alert - MTDR, ABCO And CTIC Traded By Insiders
at The Street - Mon Aug 18, 9:15AM CDT
Stocks with insider trader activity include MTDR, ABCO and CTIC
ABCO: 48.47 (-5.78), CTIC: 2.13 (-0.23), MTDR: 24.03 (+1.54)
Insider Trading Alert - CMS, CTIC And WFT Traded By Insiders
at The Street - Thu Aug 07, 9:15AM CDT
Stocks with insider trader activity include CMS, CTIC and WFT
CMS: 32.91 (+0.54), WFT: 15.67 (+0.29), CTIC: 2.13 (-0.23)
FDA Grants Fast Track Designation to CTI BioPharma's Pacritinib, a Novel JAK2 Inhibitor for the Treatment of Myelofibrosis
PR Newswire - Thu Aug 07, 12:30AM CDT
CTI BioPharma Corp. (CTI or the Company) (NASDAQ and MTA: CTIC) announced today that pacritinib has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of intermediate and high risk myelofibrosis, including but not limited to patients with disease related thrombocytopenia, patients experiencing treatment emergent thrombocytopenia on other JAK2 therapy or patients who are intolerant to or whose symptoms are sub-optimally managed on other JAK2 therapy. Pacritinib is an oral tyrosine kinase inhibitor with dual activity against JAK2 and FLT3. The drug candidate is currently being evaluated in two Phase 3 clinical trials, known as the PERSIST program, for patients with myelofibrosis.
CTIC: 2.13 (-0.23)
